A drug once dismissed as ineffective in patients with chronic lymphocytic leukemia has shown promising results in two phase I and II clinical trials, according to new research.
A drug once dismissed as ineffective in patients with chronic lymphocytic leukemia has shown promising results in two phase I and II clinical trials, according to new research.